ArticleInternational journal of biological sciences2019
Andrographolide Enhances TRAIL-Induced Apoptosis via
Article in International journal of biological sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 46 citations in OpenAlex.
- 5-Aminoimidazole-4-carboxamide riboside, an AMPK activator, enhances TRAIL-mediated apoptosis in human bladder cancer cells in a p38 MAPK-dependent manner.Genes & genomics · 2026Article
- Combination Therapy with Betulinic Acid and TRAIL Increases ROS-Dependent Cytotoxicity and Inhibits PI3K/Akt Signaling in Human Bladder Cancer Cells.Biomolecules & therapeutics · 2026Article
- Traditional Chinese medicine in non-muscle-invasive bladder cancer: a scoping review of syndrome characteristics and critical synthesis of pharmacological and mechanistic evidence.Frontiers in pharmacology · 2026Review
- Review
- Current Evidence on Molecular Mechanisms of Andrographolide in Cancer.Current medicinal chemistry · 2025Review
- Gintonin-EnrichedCurrent issues in molecular biology · 2024Article
- Article
- TRAIL-mediated signaling in bladder cancer: realization of clinical efficacy of TRAIL-based therapeutics in medical oncology.Medical oncology (Northwood, London, England) · 2023Review
- Modulation of Spheroid Forming Capacity and TRAIL Sensitivity by KLF4 and Nanog in Gastric Cancer Cells.Current issues in molecular biology · 2022Article
- Exploring the mechanism of andrographolide in the treatment of gastric cancer through network pharmacology and molecular docking.Scientific reports · 2022Article
- Rhein promotes TRAIL-induced apoptosis in bladder cancer cells by up-regulating DR5 expression.Aging · 2022Article
- Anti-cancer activity of heteroaromatic acetals of andrographolide and its isomers.New journal of chemistry = Nouveau journal de chimie · 2022Article
- Andrographolide Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells by Interfering with NF- κ B and PI3K/AKT Signaling In Vitro and In Vivo.Chinese journal of integrative medicine · 2022Article
- Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant EfficacyFrontiers in oncology · 2022Article
- Kaempferol sensitizes tumor necrosis factor-related apoptosis-inducing ligand-resistance chronic myelogenous leukemia cells to apoptosis.Molecular biology reports · 2022Article
- Biological properties of andrographolide, an active ingredient ofAnnals of translational medicine · 2021Review
- Antitumor effects of Andrographis via ferroptosis-associated genes in gastric cancer.Oncology letters · 2021Article
- Traditional Chinese medicines and their active ingredients sensitize cancer cells to TRAIL-induced apoptosis.Journal of Zhejiang University. Science. B · 2021Review
- Harnessing TRAIL-Induced Apoptosis Pathway for Cancer Immunotherapy and Associated Challenges.Frontiers in immunology · 2021Review
- The Adroitness of Andrographolide as a Natural Weapon Against Colorectal Cancer.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an effective chemotherapeutic agent that specifically impairs cancer cells while sparing normal cells; however, some cancer cells develop resistance to TRAIL. Here, we identified Andrographolide, a diterpenoid lactone derived from a traditional herbal medicine
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.